Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28457619
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 EBioMedicine
2017 ; 19
(ä): 91-97
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Borrelia burgdorferi-specific IgA in Lyme Disease
#MMPMID28457619
D'Arco C
; Dattwyler RJ
; Arnaboldi PM
EBioMedicine
2017[May]; 19
(ä): 91-97
PMID28457619
show ga
The laboratory diagnosis of Lyme disease is currently dependent on the detection
of IgM and IgG antibodies against Borrelia burgdorferi, the causative agent of
the disease. The significance of serum IgA against B. burgdorferi remains
unclear. The production of intrathecal IgA has been noted in patients with the
late Lyme disease manifestation, neuroborreliosis, but production of
antigen-specific IgA during early disease has not been evaluated. In the current
study, we assessed serum IgA binding to the B. burgdorferi peptide antigens, C6,
the target of the FDA-cleared C6 EIA, and FlaB(211-223)-modVlsE(275-291), a
peptide containing a Borrelia flagellin epitope linked to a modified VlsE
sequence, in patients with early and late Lyme disease. Specific IgA was detected
in 59 of 152 serum samples (38.8%) from early Lyme disease patients.
Approximately 50% of early Lyme disease patients who were seropositive for
peptide-specific IgM and/or IgG were also seropositive for peptide-specific IgA.
In a subpopulation of patients, high peptide-specific IgA could be correlated
with disseminated disease, defined as multiple erythema migrans lesions, and
neurological disease complications. These results suggest that there may be an
association between elevated levels of antigen-specific IgA and particular
disease manifestations in some patients with early Lyme disease.
free
free
free
